Reuters logo
BRIEF-Galectin Therapeutics Announces Results From Phase 2b NASH-CX Trial Of GR-MD-02
December 5, 2017 / 2:00 PM / 9 days ago

BRIEF-Galectin Therapeutics Announces Results From Phase 2b NASH-CX Trial Of GR-MD-02

Dec 5 (Reuters) - Galectin Therapeutics Inc:

* GALECTIN THERAPEUTICS ANNOUNCES RESULTS FROM PHASE 2B NASH-CX TRIAL OF ITS PROPRIETARY COMPOUND GR-MD-02

* GALECTIN - PHASE 2B TRIAL NASH-CX SHOWED STATISTICALLY SIGNIFICANT RESULTS IN REDUCING PRIMARY ENDPOINT MEASUREMENT OF HVPG VERSUS PLACEBO

* GALECTIN - FOR MAJOR SECONDARY ENDPOINT ASSESSMENT OF LIVER BIOPSY, SAW STATISTICALLY SIGNIFICANT EFFECT OF TREATMENT TO IMPROVE HEPATOCYTE BALLOONING

* GALECTIN - THERE WAS STATISTICALLY SIGNIFICANT REDUCTION IN DEVELOPMENT OF NEW ESOPHAGEAL VARICES IN PATIENTS WITHOUT VARICES AT BASELINE

* GALECTIN-THERE WAS POSITIVE TREND IN TOTAL GROUP,BUT DIFFERENCE DID NOT REACH STATISTICAL SIGNIFICANCE IN REDUCING PRIMARY ENDPOINT MEASUREMENT OF HVPG​‍​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below